Alexza initiates second phase 3 trial of Staccato loxapine
Tuesday, July 29, 2008 13:00 IST Mountain View, California
Alexza Pharmaceuticals, Inc. has initiated its second phase 3 clinical trial with AZ-004 (Staccato loxapine). AZ-004 is an inhalation product candidate being developed for the treatment of acute agitation in patients